# Bone-modification-agent-and-prostate-cancer
Performed data cleaning, univariate, bivariate and multivariate analysis with Statistical Analysis Software version 9.4 (SAS) 
to analyze the association between bone modification agents and prostate cancer
The results showed that patients diagnosed with prostate cancer and bone metastasis often start with BMAs more than a year after diagnosis.
The study provided insight into potential obstacles to receiving adequate bone modifying therapy and demonstrates the importance of accessible dental care in providing optimal treatment for patients with metastatic prostate cancer.
